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Abstract
Background: Within the field of plastic surgery, free tissue transfer is common practice for knee and lower leg
defects. Usually, after such free flap reconstruction, patients undergo a dangling protocol in the postoperative
phase. A dangling protocol is designed to gradually subject the free flap to increased venous pressure resulting
from gravitational forces. Worldwide there are multiple variations of dangling protocols. However, there is no
evidence available in the literature that supports the use of a dangling protocol.
Methods: This is a multicenter randomized controlled trial that includes patients with a free flap lower leg
reconstruction. The primary outcome is to assess whether a no-dangling protocol is not inferior to a dangling
protocol, in terms of proportion of partial flap loss, 6 months after surgery. Secondary objectives are to identify
differences in major and minor complications, length of stay, and costs, and to objectify blood gaseous changes
during dangling. Furthermore, at 2 years we will assess difference in physical function, infection rates, and osseous
union rates.
Discussion: The primary outcome of this study will give a more decisive answer to the question of whether a
dangling protocol is necessary after a free flap reconstruction of the lower leg. The secondary outcomes of this
study will provide a better insight into the physical functions, infection rates, and union rates in these patients.
Trial registration: Central Committee on Research Involving Human Subjects (CCMO), NL63146.041.17. Registered
on 11 July 2018. Netherlands Trial Register, NTR7545. Registered on 10 October 2018.
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Background
Within the field of plastic surgery, free tissue transfer is
common practice. In knee and lower leg defects due to
trauma, oncological resection, or chronic infection, ad-
equate soft tissue coverage of bony structures is
imminent. In case of insufficient bony coverage, a
muscle or fasciocutaneous (skin, fat, and fascia) free tis-
sue transplantation is performed. This is a microsurgical
operation in which distant body tissue is transplanted to
the defect. However, there is great diversity in the post-
operative care for patients with a lower leg reconstruc-
tion. Usually, after such free flap reconstruction, patients
undergo a dangling protocol in the postoperative phase.
During this dangling protocol, the patients hang the re-
constructed lower leg from the side of the bed in order
to gradually subject the free flap to increased venous
pressure resulting from gravitational forces. Worldwide
there are multiple variations of dangling protocols. The
starting point, frequency, and duration vary widely;
whereas some start the dangling protocol as early as on
the second postoperative day (POD), others wait until
the fourth postoperative week [1–3]. Some report not to
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use dangling as a standard procedure at all [1], and some
use it only in select cases [2]. In general, the dangling
protocol is performed in a hospital setting. Although not
supported by any evidence, dangling protocols are de-
signed to decrease the risk of postoperative complications
such as partial or total flap necrosis. These protocols usu-
ally extend hospital stay, resulting in higher costs.
Jokuszies et al. [4] and Neubert et al. [5] performed the
only two known randomized controlled trials in this pa-
tient group. They compared an early start of the dangling
protocol on POD 3 to the more standard starting point on
POD 7. Both studies showed that the combined wrapping
and dangling procedure can safely be started at POD 3. It
must be noted that the patients included in these studies
were for the most part the same group of patients. Fur-
thermore, the numbers of patients in both studies were
small (31 and 49), resulting in an underpowered study [4,
5]. McGhee et al. published a systematic review compar-
ing an early dangling protocol to a late dangling protocol
[6]. They found eight relevant articles, including the stud-
ies performed by Jokuszies et al. [4] and Neubert et al. [5].
Based on the currently available literature, they concluded
that an early dangling protocol can be safely used. A more
recent systematic review by Soteropulos et al. came to a
similar conclusion [7].
Both systematic reviews are calling for a larger ran-
domized controlled trial. Moreover, whether or not to
dangle at all is an intriguing question. We hypothesize
that the free flap as a result of flap ingrowth regains its
venoarterial response and will develop increased venous
outflow over time. We believe that this is independent of
a dangling protocol. Therefore, we designed a study
protocol for a large multicenter randomized controlled
trial, which we present in this article.
Objectives
The primary objective is to assess whether a no-dangling
protocol is not inferior to a dangling protocol. Our
primary outcome is measured in terms of proportion of
patients who experienced partial flap loss which did not
require another free flap procedure. Total follow-up for
our primary objective is 6 months. Based on a rate of
partial flap loss of 6%, we decided that an absolute
increase in incidence of 12% would be clinically signifi-
cant. We will calculate the absolute risk differences in
incidence of partial flap loss (major and minor com-
bined) between groups.
We also have the following secondary objectives:
– We hypothesize that there is no difference in one or
more major complications at 6 months.
– We would like to objectify the gaseous changes
within the free flap during the dangling protocol in a
select group of patients.
– We will measure the physical functions at 3 and 6
months and at 1, 1.5, and 2 years with the Patient-
Reported Outcomes Measurement Information
System (PROMIS) physical function, EuroQol five
dimensions (EQ-5D), and visual analog scale (VAS)
questionnaires.
– We hypothesize that there is no difference in the
number of patients experiencing one or more minor
complications at 3 and 6 months postoperatively.
– We will investigate whether there is a difference in
the length of hospital stay between the two groups
and perform a costs analysis.
– We will investigate infection rates and osseous
union rates with a follow-up of 2 years.
Methods/design
Trial design
The study is taking place at three Dutch hospitals: Uni-
versity Medical Center (UMC) Utrecht, Erasmus Univer-
sity Medical Center (Erasmus MC) Rotterdam, and
UMC Groningen. A dangling protocol is the current
standard of care in these hospitals. Patients are randomly
assigned by a computer program to group A or B. Pa-
tients in group A start a dangling protocol on POD 7.
Patients in group B can mobilize without limitations
starting on POD 7 and are discharged from the hospital
when possible. All patients will be seen on POD 12–15,
after 5–7 weeks, 2.5–3.5 months, and 5–7 months at the
ward or the outpatient clinic. During these visits the
complications will be evaluated. The study phases and
data collection time points are shown in Fig. 1. The
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist is provided as Add-
itional file 1.
Patients in group A (dangling) at the UMC Utrecht
will undergo blood tests with the use of a point-of-care
testing (POCT) device. A drop of blood will be taken on
a daily basis from both the flap and from the contralat-
eral leg (control) and will subsequently be analyzed for
pO2, pCO2, and pH levels. Moreover, all patients will be
asked to fill out three short (PROMIS, EQ-5D, and VAS)
online questionnaires at 3 and 6months and at 1, 1.5,
and 2 years postoperative. The inclusion and exclusion
criteria are listed in Table 1.
Study parameters
As our primary study parameter we will investigate
whether there is a significant increase in the incidence of
partial flap loss in patients who did not undergo a
dangling protocol (group B) versus patients who did
undergo a dangling protocol (group A). We defined
complete flap necrosis, partial flap necrosis (if a revision
surgery with a second free flap is necessary), and
pulmonary embolism as major complications. Screening
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for pulmonary embolism will only be performed if
there is a clinical suspicion of a pulmonary embolism.
Partial flap loss is defined as a minor complication if
no secondary free flap is needed or as a major
complication if a secondary free flap was needed.
Wound dehiscence, wound infection, failure of skin
graft ingrowth on the free flap, and hematoma for
which a surgical exploration was needed were defined
as minor complications.
Randomization
Randomization will be performed in Castor EDC,
Amsterdam, the Netherlands. This study cannot be
blinded. The randomization is stratified per medical
center. The coordinating researcher will log in to the
computer system and fill out the required information.
In case of a re-intervention, the patient will still be
included in the study. If the arterial and/or venous anas-
tomosis required a redo, then the day of the performed
re-intervention will be POD 0. The study (dangling or
no-dangling protocol) will start 7 days after the re-
intervention.
In case the patient has a partial or complete flap loss
and a secondary free flap transplantation is indicated,
the patient will not be re-invited to join the study for
randomization after the secondary free flap.
STUDY PERIOD
Enrolment Operation Post-allocation Close out Follow up Close out
TIMEPOINT -t1 0 Day 7 2wk 6wk 3M 6M 1 yr 1,5yr 2 yr
ENROLMENT:
Eligibility screen X
Informed consent X
Randomization X X
INTERVENTIONS:
Group A Dangle 
Group B No Dangle X
ASSESSMENTS:
Baseline variables X X X
Physical 
examination X X X X X
Adverse events X X X X X
Photographs X X X X X
POCT (UMCU)
Patient file analysis X X X X X X X X
Surveys X X X X X
Statistical analysis X X
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure showing the phases of the trial and data collection
time points
Table 1 Inclusion and exclusion criteria for “the dangle study”
Inclusion criteria - Male or female
- Age between 18 and 99 years old
- Lower leg defect in need of a free flap reconstruction
Exclusion criteria - Age under 18 years
- Co-morbidities that prevent the patient from being able to undergo a dangling protocol
- Insufficient Dutch language skills to understand the study
- Patients who are mentally incompetent or are unable to give informed consent
- Reconstruction with 2 or more free flaps
- Patients who are getting a secondary free flap due to partial or total free flap necrosis
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Study procedures
All patients randomized to group A will undergo a
dangling protocol. In Table 2 this dangling protocol is
further specified. The flap will be wrapped during the
dangling procedure. After 5–7 weeks, 2.5–3.5 months,
and 5–7 months, the patients will be seen at the
outpatient clinic to evaluate complications. Photographs
of the flap will be taken on POD 6 or 7 and at all
planned follow-up visits. These photos will be used in a
sample test to check whether the estimated percentage
partial flap necrosis and skin graft take was estimated
correctly.
Patients in group B are allowed to dangle for an un-
limited time starting on POD 7. Patients in group B are
allowed to go home (if the wound status and further co-
morbidities allow) and will be seen at the outpatient of-
fice between PODs 12 and 15 (depending on the week-
ends) and after 5–7 weeks, 2.5–3.5 months, and 5–7
months. From POD 7 until POD 14 patients will wear a
step counter and will keep track of the time they spent
standing or sitting with their leg down. The flap will be
wrapped starting on POD 7. During the outpatient office
visits the complications will be evaluated.
Point-of-care blood tests
All of the randomized patients in group A at the
UMC Utrecht will undergo blood tests. Using a
POCT device, a drop of blood from the free flap and
from the contralateral “healthy” leg (control group)
will be analyzed for blood gases (pO2, pCO2, pH). If
the patient has a bilateral leg injury, the drop of
blood will be taken from a different body part. This
study is designed to get a better insight into the gas-
eous changes within the free flap during the dangling
process. Blood will be taken from the free flap and
the contralateral leg at the beginning and at the end
of the dangling session. Table 3 illustrates the proto-
col for the POCT. The goal of these POCT measure-
ments is to present a curve of the gaseous changes
during a dangling protocol and to get more insight
into the effect of dangling on these blood gases.
Anticoagulant use during the study
The use of coumarins or a novel oral anticoagulant will
be preoperatively stopped. If the patient has an indica-
tion for “bridging” with a therapeutic dose of low mo-
lecular weight heparin (LMWH) due to co-morbidities,
this will be done. If bridging is not indicated, the patient
will receive a prophylactic dose of LMWH to reduce the
risk of deep venous thrombosis or pulmonary embolism,
which is standard of care for all patients undergoing sur-
gery in the Netherlands.
Patients who use acetylsalicylic acid will continue this
medication. Acetylsalicylic acid will not be started in pa-
tients after a free flap, in case the patients did not use
this medication before the operation.
Sample size calculation
Based on the incidence of partial flap necrosis in the
meta-analysis by Xiong et al., we performed a power cal-
culation [8]. Because total free flap loss rarely occurs
after POD 5, we decided to focus in this study on partial
flap loss. Based on a rate of partial flap loss of 6%, we
decided that an absolute increase in incidence of 12%
would be clinically significant. To detect this non-infer-
iority margin with 80% power and a two-sided 95% con-
fidence interval (CI) and 5% estimated loss to follow-up,
we aim to include 130 patients. Each year about a hun-
dred lower limb reconstructions are performed at our
three hospitals, resulting in an inclusion time of 2 years.
Statistical analysis
As the primary hypothesis we will calculate the absolute
risk differences in incidence of partial flap loss (major
and minor combined) between groups. If the upper limit
of the 95% CI falls within 12%, we regard this as a non-
inferiority difference.
The secondary hypotheses will be tested for superior-
ity: absolute risk difference for one or more major com-
plications and 95% CI, and linear regression for length
of stay, physical function, and blood tests.
We will perform an intention-to-treat analysis. How-
ever, since investigators can decide to withdraw a subject
from the study for life-threatening medical reasons (see
the subsequent section on Recruitment, consent, and
withdrawal), we will perform an additional per protocol
analysis and compare baseline characteristics of patients
withdrawn and patients lost to follow-up. We will use
multiple imputation to account for missing variables.
We will perform an interim analysis when 40 patients
are randomized. If we find a significant difference
through Fisher’s exact test in patients having one or
more major or minor complications, we will terminate
the trial. Based on previous studies, we will test our final
non-inferiority hypothesis without alpha adjustment for
the superiority tested interim analysis.
Table 2 Dangling protocol for patients in group A in the free
flap group
Postoperative day Duration of dangling 3 times a day
7 5 min
8 10min
9 20min
10 30min
11 45min
12 60min
13 Unlimited
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Recruitment, consent, and withdrawal
Patients will be invited by a plastic surgery resident who
is not affiliated with this study or clinically responsible
for the patient. This will be done before POD 5. The pa-
tient will then have at least 24 h to decide whether he/
she would like to join the study. The patient will be pro-
vided with an information letter and asked to give writ-
ten informed consent. The study will start on POD 7. If
a patient at the UMC Utrecht is randomized to group A
and would like to take part in the study but does not
want to have the POCT performed, then the patient will
still remain in group A (without the blood test).
Based on the current literature, there are no known in-
creased risks involved with participation in this study.
The hypothesized beneficial effect is that patients in
group B might have a shorter hospital stay.
Subjects can leave the study at any time for any reason
if they wish to do so, without any consequences. The in-
vestigator can decide to withdraw a subject from the
study for life-threatening medical reasons. If during the
study it is anticipated that there is a very high risk of
total flap necrosis, the treating physician can decide to
withdraw the patient from the dangling part of the
study. This applies to patients in both groups A and B.
This risk will be an estimation based on the clinical
experience of the surgeon. For ethical reasons, we
believe that this possibility is important in this study.
The patient will still be included for the secondary ob-
jectives. If a patient experiences an adverse event which
prevents the patient from adequately performing a
dangling or a non-dangling protocol, that patient will be
terminated from the study for the primary study out-
come. If possible, the patient will still be included for
the secondary objectives.
Study data management, oversight, and publication
Data will be handled confidentially. Data will be col-
lected in the electronic patient file by the local re-
searcher and subsequently registered in Castor EDC,
Amsterdam, the Netherlands. Patients will be anon-
ymized. The handling of personal data will be performed
in compliance with the Dutch Personal Data Protection
Act and in compliance with Good Clinical Practice
guidelines. Data will be kept for 15 years. Informed
consent from study participants will be recorded at every
hospital in the electronic patient file, and signed paper
forms will be securely locked away within the hospital
where the patient is undergoing treatment.
The study is monitored by an independent monitoring
company (Julius Clinical, Zeist, the Netherlands) accord-
ing to a detailed monitoring plan. Insurance is provided
for all participants in accordance with Dutch legislation.
The results of this study will be submitted to peer-
reviewed journals.
Discussion
This study is designed to give a more decisive answer to
the question of whether a dangling protocol is necessary
after a free flap reconstruction of the lower leg. This will
be the first randomized controlled study comparing a
non-dangling protocol to a dangling protocol. World-
wide, the current standard of care is a dangling protocol.
We believe that the length of hospitalization in a non-
dangling protocol can be significantly reduced compared
to that for a dangling protocol. This would potentially
reduce infection rates and lower costs. Furthermore,
patients undergoing a non-dangling protocol will be able
to ambulate at an earlier stage, reducing the risk of deep
vein thrombosis and pulmonary embolism.
Our POCT measurements are a novel way to provide
us with detailed information about the gaseous changes
in a free flap during dangling. Furthermore, we will be
able to give more insight into the physical functions,
infection rates, and osseous union rates for this patient
group.
At the end of this study we will have included 130
patients. This will be the largest prospective study in this
patient group. Therefore, we will also be able to collect
unique data about the physical functions, infection rates,
and union rates.
Limitations
Given that this is a non-blinded study, patients who are
randomized to the no-dangling group could implement
a dangling protocol on their own. To prevent this, we
will provide patients in this group with a step counter,
and they will have to keep track of the amount of time
that their leg was in a dangling position.
Table 3 Point-of-care testing (POCT) protocol during the dangling protocol
Postoperative day Before a dangling session At the end of a dangling session
7 POCT from flap and contralateral leg POCT from flap
8 POCT from flap and contralateral leg POCT from flap
9 POCT from flap and contralateral leg POCT from flap
10 POCT from flap and contralateral leg POCT from flap
11 POCT from flap and contralateral leg POCT from flap
12 POCT from flap and contralateral leg POCT from flap
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For ethical reasons, we believe that it is important that
the treating physician can decide to withdraw a patient
from the dangling part of the study if the physician
thinks the risk of flap necrosis is too high. However, this
could lead to treatment indication bias. However, we
should be able to account for this by intention-to-treat
or per protocol analysis.
Our sample size calculation is based on a rate of
partial flap loss of 6%. We decided that a rather high
absolute increase in incidence of 12% would be clinically
significant. If we had chosen a lower increase of
incidence the sample size would have increased signifi-
cantly, resulting in a non-feasible study.
Trial status
The study was registered at the CCMO (Central Com-
mittee on Research Involving Human Subjects) in the
Netherlands on 11 July 2018 (NL63146.041.17) and reg-
istered with the Netherlands Trial Register (registration
number NTR7545). This article is based on protocol ver-
sion number 7.0, dated 22 January 2019. Recruitment
started at the UMC Utrecht on 16 October 2018, at the
Erasmus MC Rotterdam on 17 January 2019, and at the
UMC Groningen on 29 January 2019. The approximate
date on which recruitment will be completed is 1 July
2021.
Additional file
Additional file 1: Spirit flowchart for The Dangle Study. (DOC 122 kb)
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